Document Detail

A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma.
MedLine Citation:
PMID:  25314054     Owner:  NLM     Status:  Publisher    
Background:Invasion and metastasis are the distinct biologic characteristics of cancer, resulting in an exceptionally low 5-year survival rate in pancreatic ductal adenocarcinoma (PDAC). Understanding in detail the mechanisms underlying PDAC metastasis is critical for prevention and effective interventions. Long non-coding RNAs (lncRNAs) have been documented as having a critical role in cancer development and progression.Methods:We examined the expression levels of lncRNA ENST00000480739 and osteosarcoma amplified-9 (OS-9) mRNA in a cohort of 35 PDAC patients. Cell proliferation, invasion and migration were examined with and without ENST00000480739 overexpression in PDAC cells.Results:We determined that the ENST00000480739 expression level was remarkably decreased in tumorous tissues compared with their corresponding non-tumorous tissues. The expression of ENST00000480739 was negatively associated with tumour node metastasis stage and lymph node metastasis. In addition, ENST0000048073 was an independent prognostic factor of survival time in PDAC patients following surgery. Besides, enforced expression of ENST00000480739 suppressed PDAC cells' invasion in vitro. Overexpression of ENST00000480739 significantly increased both mRNA and protein levels of OS-9, and the luciferase assays confirmed that ENST00000480739 positively regulates OS-9 by activating the transcription level of the OS-9 promoter. We further found that ENST00000480739 may target hypoxia-inducible factor-1α (HIF-1α) expression by upregulating OS-9.Conclusions:These findings suggest that the frequently downregulated ENST00000480739 in PDAC contributes to tumour metastasis and progression by regulating HIF-1α. Long non-coding RNA ENST00000480739 may provide not only a therapeutic potential to suppress metastasis but it may also be a novel biomarker for risk prognostication and personal therapy screening of PDAC patients.British Journal of Cancer advance online publication, 14 october 2014; doi:10.1038/bjc.2014.520
Y-W Sun; Y-F Chen; J Li; Y-M Huo; D-J Liu; R Hua; J-F Zhang; W Liu; J-Y Yang; X-L Fu; T Yan; J Hong; H Cao
Related Documents :
10375014 - Growth hormone suppression of insulin-like growth factor binding protein-1 promoter act...
20562914 - Cell transformation by v-rel reveals distinct roles of ap-1 family members in rel/nf-ka...
9030714 - Loss of ref-1 protein expression precedes dna fragmentation in apoptotic neurons.
15737994 - Cyclin a is a c-jun target gene and is necessary for c-jun-induced anchorage-independen...
7761434 - Antitumor promotion by phenolic antioxidants: inhibition of ap-1 activity through induc...
23326444 - Pre-mrna splicing is a determinant of nucleosome organization.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-14
Journal Detail:
Title:  British journal of cancer     Volume:  -     ISSN:  1532-1827     ISO Abbreviation:  Br. J. Cancer     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-10-14     Completed Date:  -     Revised Date:  2014-10-15    
Medline Journal Info:
Nlm Unique ID:  0370635     Medline TA:  Br J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a populati...
Next Document:  Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant...